New England Biolabs® Launches NEBNext® Enzymatic Methyl-seq (EM-seq™) for bisulfite-free methylation analysis

This new enzyme-based system allows scientists to accurately and sensitively assess DNA methylation without bisulfite treatment, for epigenetics research.

Written byNew England BioLabs
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

New England Biolabs (NEB®) today announced the launch of NEBNext® Enzymatic Methyl-seq (EM-seq), an enzyme-based alternative to bisulfite sequencing for methylation analysis.

Bisulfite treatment has long been the gold standard for methylome analysis, specifically the identification of 5mC and 5hmC. However, this harsh chemical treatment damages DNA, resulting in DNA fragmentation and loss. Sensitivity of detection and confidence in results are also reduced by the bias introduced, including in GC coverage and over-representation of methylated regions.

In response to the need for an alternative, NEB has developed NEBNext EM-seq, a conversion method that utilizes enzymatic treatment and minimizes damage to DNA. When combined with the supplied NEBNext Ultra™ II DNA Library Prep reagents, EM-seq produces high-quality libraries for next generation sequencing that enable superior detection of 5mC and 5hmC from fewer sequencing reads. Additionally, the EM-seq method results in the same sequence conversion as whole genome bisulfite sequencing (WGBS), and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo